Start-Up Previews (7/06)
Executive Summary
A preview of the emerging health care companies profiled in the current, all profiles issue of Start-Up. This month's profile groups: Post-Macugen, Still In-Licensing to Uncover Value in Ophthalmology, Neurostimulation's Billion Dollar Markets, and Antibacterial Drug Development. Plus these Start-Up Across Health Care: Ascenta Therapeutics, CircuLite, CoroNovative and Endovalve.
You may also be interested in...
Neurostimulation Market Expanding
According to Medtech Insight’s recently published report, US Markets for Neurostimulation Products, the frontier for neural stimulation is expanding rapidly, representing a $628 million market in 2006 that is forecast to grow by over 20% each year to produce sales approaching $2 billion in 2012. Topics discussed include implantable pulse generators, device reimbursement, and current and emerging applications for neurostimulation.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.